The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

• Status: Unknown status
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Microwave ablation, as a new method to therapy secondary hyperparathyroidism(SHPT), now is developing rapidly. However, it is still unknown whether it is effective to accept microwave ablation for hemodialysis patients with mild-to-moderate SHPT. In this prospective, randomised control and paried clinical trial study, the investigators will observe the efficiency and safety of microwave ablation in hemodialysis patients with mild-to-moderate secondary hyperparathyroidism. The patients in age-matched control group will accept active Vitamin D therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wenhu Liu
• Treatments: Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

1. patients with age between 18-75 years.

2. patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.

3. patients in hemodialysis, whose iPTH is between 300pg/ml and 800pg/ml.

Exclusion Criteria:

1. primary or tertiary hyperparathyroidism(hyperparathyroidism after kidney transplantation).

2. patient who underwent total parathyroidectomy.

3. Known history of parathyroid or other neoplasias in the neck region.

4. History of neck trauma.

5. major surgery of neck in the last 3 months or in next 4months.

6. pregnant or lactating woman.

7. patients with severe liver disease and abnormal blood clotting mechanism.

8. patients with chronic wasting disease.

9. patients who is taking glucocorticoids.

10. patients who have other disorders affecting calcium and phosphorus metabolism.

11. patients whose concurrent illnesses,disability,or geographical residence would hamper attendance at required study visit.